Skip Navigation

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Ind 134427 Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer

Brief Summary

Type:
Ovarian

Study Type:
Treatment

Phase:
II/III

ClinicalTrials.gov Identifier:
NCT02839707

Study #:
STUDY00142774

Start Date:
Sep 24, 2018

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT02839707

View Complete Trial Details & Eligibility at ClinicalTrials.gov